Desipramine is a tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and acts as a very potent and relatively selective norepinephrine reuptake inhibitor (NRI), which is thought to enhance noradrenergic neurotransmission. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. Based on one study, Desipramine has the highest affinity for the norepinephrine transporter (NET) of any TCA and is said to be the most noradrenergic and the most selective for the NET among the TCAs. The observed effectiveness of desipramine in the treatment of ADHD was the basis for the development of the selective NRI atomoxetine and its use in ADHD.
It also appears to impair serotonin transport. It also possesses minor anticholinergic activity, through its affinity to muscarinic receptors, as well as minor α1-blocking and antihistamine effects. However, it has the weakest antihistamine and anticholinergic effects of the TCAs.
Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. In fact unlike most others TCAs, Desipramine tends to be slightly activating/stimulating rather than sedating. Therefore, whereas other TCAs are useful for treating insomnia, desipramine can cause insomnia as a side effect due to its activating properties. The drug is also not associated with weight gain, in contrast to many other TCAs.
Secondary amine TCAs like desipramine and nortriptyline have a lower risk of orthostatic hypotension than other TCAs, although desipramine can still cause moderate orthostatic hypotension.
Storage conditions: Store in cool & dry place, Protect from light
Packaging: : polyethylene nylon plastic bag